Canada markets close in 1 hour 52 minutes

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.73+0.27 (+4.18%)
As of 2:08PM EST. Market open.
Full screen
Loading interactive chart...
  • Why Solid Biosciences Stock Is Sinking Today
    Motley Fool

    Why Solid Biosciences Stock Is Sinking Today

    The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will.

  • Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
    GlobeNewswire

    Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20 am ET. Following the prepared remarks, several members of the leadership team will be available for Q&A. Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.About Solid Biosciences Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.Investor Contact: David Carey FINN Partners 212-867-1768 David.Carey@finnpartners.comMedia Contact: Erich Sandoval FINN Partners 917-497-2867 Erich.Sandoval@finnpartners.com

  • Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress
    Zacks

    Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress

    Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.